Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has issued an update.
ImmuneOnco Biopharmaceuticals has announced the submission of a Phase III clinical trial application for IMM2510, targeting immunotherapy-resistant non-small cell lung cancer. The trial aims to verify the efficacy and safety of IMM2510, which has shown promising results in earlier studies, including a 35.3% objective response rate and a 76.5% disease control rate in patients with advanced squamous NSCLC. This development could enhance the company’s position in the oncology market by offering a potentially effective treatment option for lung cancer patients.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company focused on developing innovative treatments for cancer. The company specializes in immunotherapy solutions, with a market focus on the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. It has a collaboration agreement with Axion Bio, Inc. for the development and commercialization of its products outside this region.
Average Trading Volume: 3,464,628
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$10.42B
See more insights into 1541 stock on TipRanks’ Stock Analysis page.